Testing and Linkage to HIV Care in China: A Cluster Randomized Trial

Walter Ling, MD
Co-Lead Investigator
Director, Integrated Substance Abuse Programs, UCLA

Zunyou Wu, MD, PhD
Co-Lead Investigator

China Center for Diseases Control and Prevention

The high proportions of patients lost at each step along the continuum of HIV care result in suboptimal benefits of life-saving antiretroviral therapy (ART) in developing countries. This project examined the effects of a hospital-based structural intervention (One4All) designed to ensure that HIV-positive individuals receive a confirmed HIV diagnosis and determination of treatment eligibility. The primary aim was to determine whether implementation of the One4All intervention increases the propotion of HIV-positive, treatment-eligible patients who are identified and linked to ART and who achieve VL suppression, thereby reducing mortality.

CTN-0056 Study Protocol


In the One4All group, 177 (76%) of 232 patients achieved testing completeness within 30 days versus 63 (26%) of 246 in the standard-of-care group (odds ratio 19.94, 95% CI 3.86-103.04, p=0.0004). Although no difference was observed between study groups in the number of hospital admissions at 90 days, by 12 months there were 65 deaths (28%) in the One4All group compared with 115 (47%) in the standard-of-care group (Cox proportional hazard ratio 0.44, 0.19-1.01, p=0.0531).

Results Article: Wu Z, Tang Z, Mao Y, et al. Testing and Linkage to HIV Care in China: A Cluster-Randomised Trial. Lancet HIV 2017;4(12):e555-e565. [get article]



Publications about CTN-0056-Ot (NCT02084316)

NIDA protocol page

Pacific Region (Lead) search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 5/2018 --